Jan W. Pitchford Inducted into Lambda Alpha International Land Economics Society
Jan’s induction into the Society exemplifies her reputation as an influential lawyer in the specialized area of land economics.
This post is an authorized copy of a press release and was not written by LegalReader.
Jan’s induction into the Society exemplifies her reputation as an influential lawyer in the specialized area of land economics.
One kilogram of fentanyl has the potential to kill 500,000 people. 6 out of 10 illegal fentanyl tablets sold on U.S. streets now contain a potentially lethal dose of the drug.
APHIS has notified U.S. industry and updated requirements in the Phytosanitary Export Database system on October 24 to allow shipments to initiate under the interim conditions that Ecuador set.
“Welcoming these outstanding public servants and well-known officials reflects the firm’s commitment to serve our clients with the highest caliber legal advisors.” ~ Founder, Nick Oberheiden
The new strategy involves additional investment of more than $100 million per year in generative AI, doubles down on build, buy, and partnership strategy outlined earlier this year, including the $650 million acquisition of Casetext, rolls out generative AI skills in flagship product, Westlaw Precision, available in the United States on Nov. 15, and sets out AI upskilling for its 26,000-person global workforce with learning and development pathways.
New offering captures evidence of health economics value of novel digital therapeutics to increase market access while reducing financial burden on the healthcare ecosystem.
U.S. Department of Agriculture Releases Final Rule After Two Decades of Foot Dragging and Political Interference.
New solution transforms legal work with the fastest legal generative AI on the market, delivering fully encrypted, secure interactions with accurate results in seconds.
Inaugural study examines common legal agreements consumers engage with and offers guidance on avoiding risky pitfalls.
The Reform Pharma initiative seeks to end direct-to-consumer pharmaceutical advertising in the United States, the only nation besides New Zealand that allows this practice.